Gunin Gupta is Co-Founder and Chief Business Officer at Ritivel (YC W26), an AI-native platform for regulatory document submission in life sciences. Ritivel's AI agents draft CTDs, CSRs, INDs, and BLAs in minutes instead of weeks, helping drugs reach patients faster.

Gunin graduated from IIT Bombay and worked as a Business Analyst at AT Kearney, focusing on sustainability and energy process industries. He previously worked at Niyo and Nomura Research Institute, gaining experience in consulting and business development.

After 50+ conversations with pharma professionals, Gunin and his co-founders discovered the critical bottleneck in regulatory submissions and built Ritivel to solve it. The company was accepted into Y Combinator's Winter 2026 batch.

Ritivel integrates with SharePoint, Veeva, and Outlook to automate document retrieval and follow-ups. The platform generates comprehensive first drafts directly in Microsoft Word, following FDA formatting requirements with citations linked to original sources.

Every month a drug is delayed costs pharma companies approximately $45M in lost revenue and delays treatment for thousands of patients. Ritivel's AI agents transform regulatory workflows, enabling teams to focus on review and refinement rather than administrative overhead.